The project won the first competition of the Virtual Research Institute program. It gained recognition from an international group of experts due to its great scientific and commercialization potential. The project's key personnel were also rated very highly. Its members have numerous achievements related to scientific activity and its commercialization. The researchers from the largest centers in Poland, including the Medical University of Warsaw, join the study.
The team consisted of Prof. Andrzej Dziembowski (project leader), Prof. Marta Miączyńska and Prof. Marcin Nowotny from the International Institute of Molecular and Cell Biology, Prof. Jacek Jemielity from the Center for New Technologies of the University of Warsaw, Joanna Kowalska, MD, PhD, from the Faculty of Physics of the University of Warsaw, Prof. Dominika Nowis from the Laboratory of Experimental Medicine MUW, Prof. Jakub Gołąb from the Department of Immunology MUW, and Prof. Robert Hołyst from the Institute of Physical Chemistry of the Polish Academy of Sciences. The researchers aim to create new technologies to increase the stability and translational potential of ribonucleic acid (mRNA) used in cancer immunotherapy. The researchers from our university will evaluate the efficacy of modified mRNAs in preclinical cancer models.
- This is a strategic project for us, which will enable us to focus the scientific work of the Laboratory of Experimental Medicine and the Department of Immunology of our University on one of the most dynamically developing areas of medicine - emphasizes Prof. Gołąb.
The funding will go to the researchers as part of the Virtual Research Institute (WIB). The institute is a nationally innovative formula for conducting research with potential for high socio-economic applications. Funds for the VRI (WIB) come from the Polish Science Fund.